Genetic polymorphisms influencing antihypertensive drug responses

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Genetics

Background:

• Hypertension significantly contributes to cardiovascular disease morbidity and mortality.
• Inter-individual genetic variability is a key factor influencing the efficacy of antihypertensive therapies.
• Optimizing hypertension treatment requires understanding genetic influences on drug response.

Purpose of the Study:

• To review genetic variations affecting responses to major antihypertensive drug classes.
• To highlight the importance of pharmacogenetics in tailoring hypertension therapy.
• To emphasize the goal of maximizing treatment efficacy and minimizing adverse effects.

Main Methods:

• Literature review of genetic polymorphisms and their impact on antihypertensive drug response.
• Analysis of studies on angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), diuretics, calcium channel blockers (CCBs), and beta-blockers.
• Synthesis of findings on genetic factors influencing drug efficacy and safety.

Main Results:

• Specific genetic polymorphisms significantly modulate patient responses to various antihypertensive drug classes.
• Variability in drug response is influenced by genetic factors, necessitating personalized treatment approaches.
• Environmental and epigenetic factors also play a role in observed variations in drug responses.

Conclusions:

• Studying genetic polymorphisms is crucial for optimizing individual antihypertensive therapy.
• Personalized medicine approaches in hypertension management aim for improved efficacy and reduced adverse events.
• Further research is needed to translate genetic findings into clinical practice for hypertension treatment.